MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 24, 2007; DOI: 10.1124/mol.107.038968


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.038968v1
72/5/1369    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chiaro, C. R.
Right arrow Articles by Perdew, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiaro, C. R.
Right arrow Articles by Perdew, G. H.


Received for publication June 13, 2007.
Revised August 23, 2007.
Accepted for publication August 24, 2007.

Evidence for an Ah receptor-mediated cytochrome P450 auto-regulatory pathway

Christopher R. Chiaro 1, Rushang D. Patel 1, Craig B. Marcus 2, Gary H. Perdew 1*

1 Pennsylvania State University 2 University of New Mexico

* Address correspondence to: E-mail: ghp2{at}psu.edu

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor responsible for mediating the cellular response to the toxic compound 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD). An essential role for the AhR in cellular biology has been previously established, but no high affinity endogenous ligand has yet been identified. We have confirmed the presence of a putative endogenous ligand(s) in CV-1 cells through transient transfection with various cytochrome P450 isoforms. Expression of cytochrome P450s 1A1, 1A2 or 1B1 reduced AhR-mediated luciferase reporter activity, while cytochrome P450 2E1 exhibited no significant effect. Studies with 2,4,3',5'-tetramethoxystilbene (TMS), a potent and specific inhibitor of cytochrome P450 1B1, was able to partially block cytochrome P450 1B1-mediated reduction in reporter gene activity. These results provide evidence of the existence of a possible feedback mechanism in which AhR regulated cytochrome P450s from the CYP1A and CYP1B families are able to metabolically alter putative endogenous ligand(s). Several experiments were performed to provide initial characterization of these putative endogenous ligands. Including electrophoretic mobility shift assays (EMSA) analysis which demonstrated that these ligands directly activate the AhR. Soluble extracts from various C57BL/6J and Ahr-null mouse tissues were also analyzed for the presence of AhR activators. Studies revealed that Ahr-null mouse lung tissue had a four-fold increase in AhR-mediated reporter activity in cells. Quantitative PCR analysis revealed that lung tissue exhibits relatively high constitutive CYP1A1 mRNA levels. These results suggest that there is an autoregulatory feedback loop between the AhR and cytochrome P450 1A1 in mouse lung.


Key words: Regulation of gene expression, Cytochrome P450, Ah receptor


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
D. E. Conway, Y. Sakurai, D. Weiss, J. D. Vega, W. R. Taylor, H. Jo, S. G. Eskin, C. B. Marcus, and L. V. McIntire
Expression of CYP1A1 and CYP1B1 in human endothelial cells: regulation by fluid shear stress
Cardiovasc Res, March 1, 2009; 81(4): 669 - 677.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. Dragin, Z. Shi, R. Madan, C. L. Karp, M. A. Sartor, C. Chen, F. J. Gonzalez, and D. W. Nebert
Phenotype of the Cyp1a1/1a2/1b1(-/-) Triple-Knockout Mouse
Mol. Pharmacol., June 1, 2008; 73(6): 1844 - 1856.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics